Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: To test or not to test, that is the question

Cancer

Volumn 113, Issue 7, 2008, Pages 1502-1510

  Deeken, John F ^a   Slack, Rebecca ^a   Marshall, John L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Irinotecan; Neutropenia; Pharmacogenomics; SN 38; Topoisomerase inhibitor; Uridine diphosphate glucuronosyltransferase 1A1

Indexed keywords

ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; ENZYME INHIBITOR; GLUCURONOSYLTRANSFERASE; IRINOTECAN;

BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DIARRHEA; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; NEUTROPENIA; PROMOTER REGION; REVIEW; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; ENZYME INHIBITORS; GLUCURONOSYLTRANSFERASE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; NEUTROPENIA; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK ASSESSMENT;

EID: 54049120234     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23777     Document Type: Review

References (43)

1. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119-137. (Pubitemid 43261982)
2. Ando Y, Hasegawa Y. Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab Rev. 2005;37:565-574. (Pubitemid 41434162)
3. Deeken JF, Figg WD, Bates SE, Sparreboom A. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs. 2007;18:111-126. (Pubitemid 44967422)
4. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 2006;24:4534-4538. (Pubitemid 46630947)
5. Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res. 2005;573:180-194.
6. Nagar S, Blanchard RL. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev. 2006;38:393-409. (Pubitemid 44167197)
7. Aono S, Yamada Y, Keino H, et al. Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II. Biochem Biophys Res Commun. 1993;197:1239-1244.
8. Koiwai O, Nishizawa M, Hasada K, et al. Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP- glucuronosyltransferase. Hum Mol Genet. 1995;4:1183-1186.
9. Bosma PJ, Chowdury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333:1171-1175.
10. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999;65:576-582. (Pubitemid 29237332)
11. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics. 2002;2:43-47. (Pubitemid 34982202)
12. Desai AA, Innocenti F, Ratain MJ. Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene. 2003;22:6621-6628. (Pubitemid 37372342)
13. Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006;20:163-175. (Pubitemid 43087700)
14. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921-6926. (Pubitemid 32059164)
15. Innocenti F, Ratain MJ. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 2004;75:495-500.
16. Hahn KK, Wolff JJ, Kolesar JM. Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm. 2006;63:2211-2217. (Pubitemid 44851434)
17. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382-1383.
18. Rouits E, Boisdron-Celle M, Dumont A, et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res. 2004;10:5151-5159. (Pubitemid 39099790)
19. Marcuello E, Altes A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer. 2004;91:678-682. (Pubitemid 39141623)
20. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005;11:1226-1236. (Pubitemid 40175775)
21. Massacesi C, Terrazzino S, Marcucci F, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer. 2006;106:1007-1016.
22. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061-3068. (Pubitemid 46638941)
23. Parodi LA, Cisar LA, Pickering E, et al. Multivariate predictive models of neutropenia associated with irinotecan treatment in previously untreated patients with colorectal cancer: a comparison of infusional and bolus regimens. Poster presented at the 2007 Gastrointestinal Cancers Symposium, Orlando, Florida, January 19-21, 2007.
24. Camptosar [package insert]. New York, NY: Pfizer Inc; 2006.
25. Tukey RH, Strassburg CP, Mackenzie PI. Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol. 2002;62:446-450. (Pubitemid 36329361)
26. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006;7:1211-1221. (Pubitemid 46024184)
27. Paoluzzi L, Singh AS, Price DK, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol. 2004;44:854-860. (Pubitemid 38971566)
28. Ramchandani RP, Wang Y, Booth BP, et al. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 2007;47:78-86. (Pubitemid 44974001)
29. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007;99:1290-1295. (Pubitemid 47394168)
30. Goetz MP, Ames MM, Weinshilboum RM. Primer on medical genomics. Pt XII: pharmacogenomics - general principles with cancer as a model. Mayo Clin Proc. 2004;79:376-384. (Pubitemid 38269239)
31. Cote JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res. 2007;13:3269-3275. (Pubitemid 46944912)
32. Innocenti F, Grimsley C, Das S, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002;12:725-733. (Pubitemid 36054939)
33. Thorn CF, Carrillo MW, Ramirez J, et al. Irinotecan pathway. PharmGKB website. Available at:http://www.pharmgkb.org/do/serve?objId=PA2001&objCls= Pathway Accessed November 29, 2007.
34. Lenz HJ. Pharmacogenomics and colorectal cancer. In: Llombart-Bosch A, Felipe V, Lopez-Guerrero JA, eds. New Trends in Cancer for the 21st Century. 2nd ed. New York, NY: Springer; 2006:211-231.
35. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics. 2004;5:835-843. (Pubitemid 39386752)
36. de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH. Role of pharmacogenetics in irinotecan therapy. Cancer Lett. 2006;234:90-106. (Pubitemid 43343943)
37. Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: what is the right star? J Clin Oncol. 2006;24:2221-2224.
38. Mathijssen RHJ, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res. 2003;9:3246-3253.
39. Mathijssen RHJ, de Jong FA, van Schaik RHN, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst. 2004;96:1585-1592. (Pubitemid 39534882)
40. Zhou Q, Sparreboom A, Tan EH, et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol. 2995;59:415-424.
41. Balram C, Li J, Zhou QY, et al. Molecular mechanisms of interethnic differences in irinotecan disposition: impact of variants in ABCG2 [abstract]. J Clin Oncol. 2005;23(Suppl). Abstract 2018.
42. Sugatani J, Kojima H, Ueda A, et al. The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology. 2001;33:1232-1238. (Pubitemid 32378224)
43. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14:2590-2611. (Pubitemid 26300128)